- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Michael Diaz on How a Delay to an OCM Successor Will Benefit Practices
"We want to make sure practices have time to learn, understand, adapt, and modify, to a new Oncology Care Model," said Michael Diaz, MD, president of Community Oncology Alliance.
"We want to make sure practices have time to learn, understand, adapt, and modify, to a new Oncology Care Model," said Michael Diaz, MD, president of Community Oncology Alliance.
Transcript:
Community Oncology Alliance (COA) recommended delaying the start of Oncology Care Model's (OCM's) successor model. How will having more time in the OCM benefit practices?
Well, there are several reasons. First of all, 2021 is less than a year away, and we don't have details on this new model. In order to have practices evolve, change, and implement new processes—and I think that's one of the key things here — there are a lot of new fundamental components that are different than the Oncology Care Model. We want to make sure that practices have adequate time to learn, understand, adapt, and modify. We're wanting to extend the Oncology Care Model in essence, to actually delay the initiation of the Oncology [Care] First model. That's the most important thing.
Some people will say, "Well, why can't you just complete the Oncology Care Model, delay the Oncology Care First model 6 months to a year?" Well, all the practices already had this Infrastructure set up for this type of system process. We have care coordinators, we have layers and layers of new systems that we've developed to be able to participate in these value-based care models, these alternative payment models. Without participating in a model, you can't keep and maintain your fundamental infrastructure. The majority of the practices, we feel, would experience some financial hardships trying to maintain those components of their practice if they're not participating in them all. We just think that it would help ease a transition.
Another more significant reason has to do with the fact that the Oncology Care First model, when you start in it, right now, the way it's designed, you start off in a 2-sided risk. We would like for as many community oncology practices to be able to participate in this, and not all are participating in the 2-sided risk of the Oncology Care Model. We just think a delay would allow more time to allow more practices to evolve to be able to participate
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
